Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.

Drug-resistant mutations (DRMs) in HIV-1 protease are a major challenge to antiretroviral therapy. Protease-substrate interactions that are determined to be critical for native selectivity could serve as robust targets for drug design that are immune to DRMs. In order to identify the structural mechanisms of selectivity, we developed a peptide-docking algorithm to predict the atomic structure of protease-substrate complexes and applied it to a large and diverse set of cleavable and noncleavable peptides. Cleavable peptides showed significantly lower energies of interaction than noncleavable peptides with six protease active-site residues playing the most significant role in discrimination. Surprisingly, all six residues correspond to sequence positions associated with drug resistance mutations, demonstrating that the very residues that are responsible for native substrate specificity in HIV-1 protease are altered during its evolution to drug resistance, suggesting that drug resistance and substrate selectivity may share common mechanisms.

[1]  F. Mammano,et al.  Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.

[2]  Sami Mahrus,et al.  Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease , 2002, Journal of Virology.

[3]  David Baker,et al.  Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.

[4]  C. Schiffer,et al.  Substrate specificity in HIV‐1 protease by a biased sequence search method , 2006, Proteins.

[5]  Celia A Schiffer,et al.  Design of HIV-1 protease inhibitors active on multidrug-resistant virus. , 2005, Journal of medicinal chemistry.

[6]  Roland L. Dunbrack,et al.  Bayesian statistical analysis of protein side‐chain rotamer preferences , 1997, Protein science : a publication of the Protein Society.

[7]  Hong Cao,et al.  Design of Mutation‐resistant HIV Protease Inhibitors with the Substrate Envelope Hypothesis , 2007, Chemical biology & drug design.

[8]  Jan Komorowski,et al.  Computational proteomics analysis of HIV‐1 protease interactome , 2007, Proteins.

[9]  Zachary Q. Beck,et al.  Molecular Basis for the Relative Substrate Specificity of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Proteases , 2001, Journal of Virology.

[10]  V. Trouplin,et al.  Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug , 2000, Journal of Virology.

[11]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[12]  Hong Cao,et al.  HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. , 2008, Journal of the American Chemical Society.

[13]  Celia A. Schiffer,et al.  Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-p1 Cleavage Site with a V82A Drug-Resistant Mutation in Viral Protease , 2004, Journal of Virology.

[14]  D B Evans,et al.  Human immunodeficiency virus type‐1 reverse transcriptase and ribonuclease h as substrates of the viral protease , 1993, Protein science : a publication of the Protein Society.

[15]  A. Israël,et al.  Processing of the precursor of NF-κB by the HIV-1 protease during acute infection , 1991, Nature.

[16]  D. Baker,et al.  A simple physical model for binding energy hot spots in protein–protein complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Karplus,et al.  Effective energy function for proteins in solution , 1999, Proteins.

[18]  Arthur J. Olson,et al.  Structural Basis for Distinctions between Substrate and Inhibitor Specificities for Feline Immunodeficiency Virus and Human Immunodeficiency Virus Proteases , 2003, Journal of Virology.

[19]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[20]  Turkan Haliloglu,et al.  Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease. , 2003, Biophysical journal.

[21]  Maureen M Goodenow,et al.  Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. , 2008, Virology.

[22]  A. Tomasselli,et al.  Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. , 1992, The Journal of biological chemistry.

[23]  Tanja Kortemme,et al.  Design of Multi-Specificity in Protein Interfaces , 2007, PLoS Comput. Biol..

[24]  T. Copeland,et al.  Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.

[25]  David Baker,et al.  Protein-protein docking with backbone flexibility. , 2007, Journal of molecular biology.

[26]  J. Tözsér,et al.  Amino Acid Preferences for a Critical Substrate Binding Subsite of Retroviral Proteases in Type 1 Cleavage Sites , 2005, Journal of Virology.

[27]  R E Cachau,et al.  Inhibition and catalytic mechanism of HIV-1 aspartic protease. , 1996, Journal of molecular biology.

[28]  D. Lamarre,et al.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.

[29]  C. Schiffer,et al.  How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. , 2000, Journal of molecular biology.

[30]  M. Oswald,et al.  Fibronectin is a non‐viral substrate for the HIV proteinase , 1991, FEBS letters.

[31]  I. Weber,et al.  Amino Acid Preferences of Retroviral Proteases for Amino-Terminal Positions in a Type 1 Cleavage Site , 2008, Journal of Virology.

[32]  Celia A Schiffer,et al.  Combating susceptibility to drug resistance: lessons from HIV-1 protease. , 2004, Chemistry & biology.

[33]  O. Schueler‐Furman,et al.  Improved side‐chain modeling for protein–protein docking , 2005, Protein science : a publication of the Protein Society.

[34]  C. Debouck,et al.  Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease. , 1992, Biochemistry.

[35]  Peteris Prusis,et al.  A Look Inside HIV Resistance through Retroviral Protease Interaction Maps , 2007, PLoS Comput. Biol..

[36]  Arthur J. Olson,et al.  Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease , 2000, Journal of Virology.

[37]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[38]  E. Wimmer,et al.  Proteolytic processing of polyproteins in the replication of RNA viruses. , 1989, Biochemistry.

[39]  Jeffrey J. Gray,et al.  Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. , 2003, Journal of molecular biology.

[40]  K. Chou Prediction of human immunodeficiency virus protease cleavage sites in proteins. , 1996, Analytical biochemistry.

[41]  J. Martinez-Picado,et al.  Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. , 2000, Virology.

[42]  Irene T Weber,et al.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV‐1 protease mutants with substrate analogs , 2005, The FEBS journal.

[43]  B. Tidor,et al.  Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV‐1 protease , 2008, Proteins.

[44]  B. Kuhlman,et al.  Structure-based protocol for identifying mutations that enhance protein-protein binding affinities. , 2007, Journal of molecular biology.

[45]  Yiying Zhang,et al.  Specificity rule discovery in HIV-1 protease cleavage site analysis , 2008, Comput. Biol. Chem..

[46]  Thorsteinn S. Rögnvaldsson,et al.  Comprehensive Bioinformatic Analysis of the Specificity of Human Immunodeficiency Virus Type 1 Protease , 2005, Journal of Virology.

[47]  N. Gautham,et al.  Exploring conformational space using a mean field technique with MOLS sampling , 2007, Journal of Biosciences.

[48]  P. Kollman,et al.  Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Michael K Gilson,et al.  Evaluation of the substrate envelope hypothesis for inhibitors of HIV‐1 protease , 2007, Proteins.

[50]  C. Schiffer,et al.  Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. , 2002, Structure.

[51]  Jeffrey J. Gray,et al.  Conformer selection and induced fit in flexible backbone protein-protein docking using computational and NMR ensembles. , 2008, Journal of molecular biology.

[52]  David Baker,et al.  Recapitulation and design of protein binding peptide structures and sequences. , 2006, Journal of molecular biology.

[53]  S Foundling,et al.  Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. , 1995, Biochemistry.

[54]  S. Wodak,et al.  Assessment of CAPRI predictions in rounds 3–5 shows progress in docking procedures , 2005, Proteins.

[55]  C. Debouck,et al.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Huber,et al.  Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .

[57]  A Wlodawer,et al.  Human Immunodeficiency Virus, Type 1 Protease Substrate Specificity Is Limited by Interactions between Substrate Amino Acids Bound in Adjacent Enzyme Subsites (*) , 1996, The Journal of Biological Chemistry.

[58]  D. Baker,et al.  Native protein sequences are close to optimal for their structures. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Nikolay V. Dokholyan,et al.  Identification and Rational Redesign of Peptide Ligands to CRIP1, A Novel Biomarker for Cancers , 2008, PLoS Comput. Biol..

[60]  Garrett M Morris,et al.  Defining HIV-1 protease substrate selectivity. , 2002, Current drug targets. Infectious disorders.